Pancreatic Cancer Research

ResearcherHarbin Medical UniversityActive in the last 2 years

Yanqiao Zhang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-6206-8364; OpenAlex author ID A5075350471. Sources: OpenAlex.

Their work

Papers
12 (first author 0, last author 8)
Trials
0
Grants
0
Labs led
1
Collaborators
33
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: none · 2017: none · 2018: none · 2019: 2 papers · 2020: 3 papers · 2021: 1 paper · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 1 paper

Papers 12

  1. Molecular Subtyping and Genomic Profiling Expand Precision Medicine in KRAS Wild-Type Pancreatic Cancer. Last author DOI 10.1111/cas.16456↗
  2. Nab-paclitaxel plus S-1 followed by gemcitabine-oxaliplatin as first-line alternating sequential treatment of pancreatic ductal adenocarcinoma. Last author DOI 10.1093/oncolo/oyae207↗
  3. VDR promotes pancreatic cancer progression in vivo by activating CCL20-mediated M2 polarization of tumor associated macrophage. Co-author DOI 10.1186/s12964-024-01578-x↗
  4. HOXB9 blocks cell cycle progression to inhibit pancreatic cancer cell proliferation through the DNMT1/RBL2/c-Myc axis. Last author DOI 10.1016/j.canlet.2022.215595↗
  5. Systemic Inflammatory Biomarkers, Especially Fibrinogen to Albumin Ratio, Predict Prognosis in Patients with Pancreatic Cancer. Last author DOI 10.4143/crt.2020.330↗
  6. LINC01559 accelerates pancreatic cancer cell proliferation and migration through YAP-mediated pathway. Last author DOI 10.1002/jcp.29288↗
  7. A Chinese Retrospective Multicenter Study of First-Line Chemotherapy for Advanced Pancreatic Cancer. Co-author DOI 10.12659/msm.927654↗
  8. Ubiquitin specific peptidase 5 enhances STAT3 signaling and promotes migration and invasion in Pancreatic Cancer. Last author DOI 10.7150/jca.48536↗
  9. STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer. Last author DOI 10.1042/cs20180816↗
  10. CSN6 expression is associated with pancreatic cancer progression and predicts poor prognosis. Last author DOI 10.1080/15384047.2019.1632143↗
  11. Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness. Co-author DOI 10.1158/1078-0432.ccr-14-2437↗
  12. S-1 as monotherapy or in combination with leucovorin as second-line treatment in gemcitabine-refractory advanced pancreatic cancer: a randomized, open-label, m… Co-author DOI 10.1634/theoncologist.2014-0223↗

Closest collaborators

The 25 strongest of 33 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Changjie Lou · 7 shared papers, 2019–2024 · strength 0.79
  2. Zhiwei Li · 5 shared papers, 2015–2024 · strength 0.58
  3. Hengzhen Li · 3 shared papers, 2022–2024 · strength 0.47
  4. Lin Fang · 4 shared papers, 2019–2022 · strength 0.43
  5. Dan Su · 2 shared papers, 2020–2025 · strength 0.34
  6. Xiaona Fan · 2 shared papers, 2024 · strength 0.34
  7. Jie Lian · 3 shared papers, 2019–2021 · strength 0.30
  8. Dan Wang · 2 shared papers, 2021–2024 · strength 0.27
  9. Yang Yao · 2 shared papers, 2021–2022 · strength 0.24
  10. Zhiwei Li · 2 shared papers, 2019–2020 · strength 0.21
  11. Tongsen Zheng · 1 shared paper, 2024 · strength 0.16
  12. Chao Liu · 1 shared paper, 2020 · strength 0.11
  13. Hanzhi Cui · 1 shared paper, 2020 · strength 0.11
  14. Yuanlong Gu · 1 shared paper, 2020 · strength 0.11
  15. Wen Zhang · 1 shared paper, 2020 · strength 0.11
  16. Jun Zhou · 1 shared paper, 2020 · strength 0.11
  17. Aiping Zhou · 1 shared paper, 2020 · strength 0.11
  18. Guochao Deng · 1 shared paper, 2020 · strength 0.11
  19. Guanghai Dai · 1 shared paper, 2020 · strength 0.11
  20. Jiaqi Shi · 1 shared paper, 2019 · strength 0.10
  21. Chao Liu · 1 shared paper, 2019 · strength 0.08
  22. Qi Zhao · 1 shared paper, 2019 · strength 0.08
  23. Jiaqi Shi · 1 shared paper, 2019 · strength 0.08
  24. Zengxun Li · 1 shared paper, 2019 · strength 0.08
  25. Dacheng Xie · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.